Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431694 | 0.89 | KDR (0.40) | MAPK14KDRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6415740 | 0.87 | KDR (0.33) | MAPK14MAPK13MAPK12MAPK11CDK2 | |
| SCHEMBL6415743 | 0.82 | KDR (0.33) | CDK2KDRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6431698 | 0.75 | KDR (0.41) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6431700 | 0.71 | KDR (0.40) | CDK2KDRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5310133 | 0.71 | EPHB4 (0.38) | MAPK14KDR | |
| SCHEMBL6417723 | 0.71 | CFD (0.34) | MAPK14MAPK13MAPK12MAPK11KDR | |
| SCHEMBL5315338 | 0.71 | EPHB4 (0.38) | MAPK14KDR | |
| SCHEMBL6416705 | 0.70 | BPTF (0.38) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6419066 | 0.68 | KDM4E (0.38) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | claimed |
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | MAPK14 2261/4885MAPK13 1788/4885MAPK12 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.